SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...
Patients with pulmonary arterial hypertension will shortly have a more convenient way to treat their disease. United Therapeutics and DEKA Research & Development have received the Food and Drug ...
Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...
The FDA has cleared the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the RemUnity system. The Food and Drug Administration (FDA) has cleared the Unity ...
United Therapeutics specializes in therapies for pulmonary arterial hypertension (PAH), or high blood pressure in the lungs. Its marketed PAH portfolio includes prostacyclin analogs Remodulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results